Bicameral Congressional Letter Demands Transparency from FDA
|Yesterday 75 members of Congress, led by Rep. Chris Smith of New Jersey and Sen. James Lankford of Oklahoma, sent a letter to the Commissioner of the Food and Drug Administration demanding answers to questions about the FDA’s surprise approval of relaxed protocols for the distribution of the abortion-inducing drug regimen known as Mifeprex. The changes, announced on March 30, significantly increase the duration of pregnancy at which the drug regimen may be administered, raising it from 49 days (7 weeks) from the last menstrual period (LMP) to 70 days (10 weeks) post-LMP.